how does glp-1 agonist suppress appetite glp-1_analogs [TUSOM Recent updates on GLP-1 agonists:

FDA is requesting that the risk be removed from the warnings and precautions section of labeling for the GLP-1 obesity drugs Eli Lilly and Co.s Zepbound (tirzepatide) and Novo Nordisk A/S Saxenda (liraglutide) and Wegovy (semaglutide).

Delve into the perspectives of employers and health plans on obesity, GLP-1 coverage rates, and concerns about off-label use.

Evidence is emerging that glucagon-like peptide-1 (GLP-1) receptor agonists have anti-inflammatory and chondroprotective properties independent of their effects on weight loss

A new deal may cut the cost of weight-loss drugs, but this UVA professor warns of potential long-term risks.

After revolutionizing care for diabetes and weight loss, GLP-1 drugs are being eyed for more